Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|NS1||HRAS Inhibitor 1 KRAS Inhibitor 6||NS1 is a synthetic monobody that binds to GTP and GDP states of HRAS and KRAS, thereby inhibiting RAS dimerization and subsequent RAF activity, which may result in inhibition of cell transformation (PMID: 27820802, PMID: 29072601).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|HRAS Q61L||bladder carcinoma||sensitive||NS1||Preclinical - Cell culture||Actionable||In a preclinical study, bladder carcinoma cells expressing HRAS Q61L demonstrated sensitivity to NS1, resulting in inhibition of Mapk signaling and cell proliferation in culture (PMID: 27820802).||27820802|
|NRAS mutant||Advanced Solid Tumor||no benefit||NS1||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing an NRAS mutation did not respond to treatment with NS1 in culture, resulting in sustained downstream signaling and cell transformation (PMID: 27820802).||27820802|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|